Friday Insights: Geron Corporation, Himax Technologies, Inc., Agios Pharmaceuticals Inc, Tonix Pharmaceuticals Holding Corp.

Geron Corporation (NASDAQ:GERN) shares are up 6.83% to $4.12 in mid-day trading, after its partner, Johnson & Johnson, received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of imetelstat as a treatment for of myelofibrosis. All the 3 analysts polled by TipRanks, rate Geron stock a Buy. With a return potential of 38.55%, the stock’s 12-month consensus target price stands at $5.75.

Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares are rising 6.82% in mid-day trading to $8.14, adding to their 9% increase this week, after BofA/Merrill Lynch analyst Daniel Heyler upgraded the stock from Underperform to Buy with a price target of $8.50.

Click Here to see the performance of analyst Daniel Heyler.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares are down 12.60% to $107.15 after the company failed to impress the market with the announcements of clinical trial results. Specifically, the company unveiled data from an ongoing Phase 1 study of its leukemia drug AG-221, showing an overall response rate that was lower than the 56 percent reported earlier with fewer patients. Subsequently, Canaccord analyst reiterated a Hold rating on Agios with a $103 price target, in a research report issued today. Out of the 8 analysts polled by TipRanks, 6 rate Agios stock a Hold, while 2 rate the stock a Buy. With a return potential of 8.87%, the stock’s 12-month consensus target price stands at $115.67.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are up 10.06% to $8.97 in mid-day trading, after Akiva Felt, an analyst at Oppenheimer, initiated a Buy rating on the stock with a price target of $18. Felt wrote, “We believe Tonix is poised to emerge as an attractive play in CNS drug development with three equally compelling opportunities in fibromyalgia (Phase 3), post-traumatic stress disorder (Phase 2) and tension headache (Phase 2).”

Click Here to see the performance of analyst Akiva Felt.